Method for introducing target gene into immune cell

By freezing and thawing natural killer cells, the efficiency of gene transduction is significantly improved, and the problem of low transduction in immune cell therapy is solved, the function and activity of cells is enhanced, and more effective cellular resources are provided for immunotherapy.

CN118984877APending Publication Date: 2024-11-19GC CELL CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032972.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-06
Filing Date
2023-04-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The inefficient gene transduction of natural killer cells limits their application in immune cell therapy, especially when using viral vectors such as lentiviruses.

Method used

By freezing and thawing natural killer cells, the efficiency of gene delivery is significantly improved, and the target gene is introduced using viral vectors to optimize the phenotype of cells, providing more effective therapeutic cell resources for immunotherapy.

Benefits of technology

It improves the efficiency of gene transduction in natural killer cells, enhances its function, activity and productivity as a source of immunotherapy, especially when using lentiviral vectors, which significantly improves the efficiency of transduction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984877A_ABST
    Figure CN118984877A_ABST
Patent Text Reader

Abstract

The present invention relates to a method for efficiently expressing a gene of interest in an immune cell, more particularly a natural killer cell, using a viral vector. Under the condition that enzyme or small molecules are not added, a simple step of freezing and unfreezing the natural killer cells is added before transduction, so that the transduction efficiency of the virus vector can be remarkably improved. In particular, the present invention significantly improves the efficiency of a lentiviral vector having a low gene transfer efficiency in natural killer cells, and thus can be effectively used for preparing natural killer cells into which genes having desired properties are introduced, thereby maximizing the function, activity, and productivity of the cells with respect to immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for improving the transduction efficiency of target genes in immune cells, especially natural killer cells, via viral vectors by freezing and thawing cells. Background Art

[0002] Natural killer (NK) cells are lymphocytes that account for about 15% of blood cells and play an important role in the innate immune defense against malignant cells. Specifically, natural killer cells activate dendritic cells and induce cytotoxic T lymphocytes (CTLs) to respond specifically to tumors to eliminate tumor cells, especially directly killing malignant tumors such as sarcomas, myelomas, carcinomas, lymphomas, and leukemias. However, immune cell therapy using natural killer cells is limited by the difficulty of in vitro expansion and the differences in natural killer cell activity between patients.

[0003] Meanwhile, in T cell immunotherapy, methods are being developed to reprogram autoimmune cells to express chimeric antigen receptors to improve effectiveness against specific cancers or to overcome resistance of cancer cells to treatment. These chimeric antigen receptors have recently been applied to natural killer cells. In addition, in treatments using allogeneic natural killer cells, it is necessary to introduce exogenous genes or inhibit or overexpress intrinsic genes to maximize their function and activity as immunotherapy cells, such as expressing cytokine IL-2 to induce NK cell proliferation, thereby solving the problem of short duration of transplanted NK cells in the recipient; or inhibiting inhibitory receptors (such as KIR) on NK cells to block the immune response of the receptor. However, natural killer cells have the disadvantage of low transduction efficiency, especially when using viral vectors such as lentiviruses. Therefore, there is a need to develop more efficient gene transduction methods. In this specification, many publications and patents are referenced and cited. The disclosures of the cited publications and patent documents are incorporated herein by reference in their entirety to more clearly describe the state of the art to which the present invention belongs and the content of the present invention.

[0004] public

[0005] Technical issues

[0006] The inventors have conducted in-depth research and developed a method for effectively expressing various target genes in immune cells to maximize the function, activity and productivity of immune cells as therapeutic cell resources. The results show that the inventors have found that freezing and thawing immune cells, especially natural killer cells, before using viral vectors to introduce target genes can significantly improve the efficiency of gene delivery and can effectively obtain natural killer cells with phenotypes optimized for immunotherapy, thereby completing the present invention.

[0007] Therefore, an object of the present invention is to provide a method for expressing a target gene in immune cells.

[0008] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating tumors or infectious diseases, wherein the pharmaceutical composition comprises natural killer cells expressing the target gene by the method of the present invention.

[0009] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, the appended claims and the accompanying drawings.

[0010] Technical Solution

[0011] In one aspect of the present invention, a method for expressing a target gene in an immune cell is provided, comprising:

[0012] (a) Frozen immune cells;

[0013] (b) thawing the frozen immune cells; and

[0014] (c) Introducing a gene delivery system containing a target gene into thawed immune cells.

[0015] The inventors have conducted intensive research and developed a method for effectively expressing various target genes in immune cells to maximize the function, activity and productivity of immune cells as therapeutic cell resources. Therefore, the inventors have found that freezing and thawing immune cells, especially natural killer cells, before using viral vectors to introduce target genes can significantly improve the efficiency of gene delivery and can effectively obtain natural killer cells with phenotypes optimized for immunotherapy.

[0016] As used herein, the term "target gene" refers to a nucleic acid molecule that is inserted into a gene delivery system so that it is artificially expressed in immune cells or its natural expression is artificially increased, thereby obtaining desired properties in target immune cells. As used herein, the term "nucleic acid molecule" has the meaning of comprehensively including DNA (gDNA and cDNA) and RNA molecules. As the basic structural unit in nucleic acid molecules, nucleotides include not only natural nucleotides, but also analogs with modified sugar or base sites (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990)).

[0017] As used herein, the term "expression" refers to artificially introducing genes using a gene delivery system, causing the subject cell to express an exogenous gene or increase the natural expression of an endogenous gene, thereby making the gene replicable in the subject cell as an extrachromosomal factor or by completing chromosomal integration. Therefore, the term "expression" has the same meaning as "transfection", "transduction" or "introduction".

[0018] As used herein, the term "gene delivery system" refers to any means of delivering a gene into a cell. Gene delivery and intracellular transduction of a gene have the same meaning. At the tissue level, the term "gene transfer" has the same meaning as gene propagation. Therefore, the gene delivery system of the present invention may be described as a gene transduction system and a gene propagation system.

[0019] In order to produce the gene delivery system described in the present invention, the nucleotide sequence of the present invention is preferably present in a suitable expression construct. In the expression construct, the nucleotide sequence of the present invention is preferably operably linked to a promoter. The term "operably linked" as used herein relates to a functional connection between a nucleotide expression regulatory sequence (e.g., a promoter, a signal sequence, or a transcriptional regulatory factor binding site array) and another nucleotide sequence, through which the regulatory sequence regulates the transcription and / or translation of other nucleotide sequences. The promoter connected to the nucleotide sequence of the present invention is a promoter that can act in animal cells, particularly in mammals, to regulate the transcription of the target gene, including, for example, promoters derived from mammalian viruses and promoters derived from mammalian cell genomes. Examples of promoters include, but are not limited to, mammalian cytomegalovirus (CMV) promoters, adenovirus late promoters, vaccinia virus 7.5K promoters, SV40 promoters, HSV tk promoters, RSV promoters, EF1α promoters, metallothionein promoters, β-actin promoters, human IL-2 gene promoters, human IFN gene promoters, human IL-4 gene promoters, and human GM-CSF gene promoters.

[0020] The nucleotide sequence of the target gene is applicable to any gene delivery system that can be used for general gene introduction. Preferably, the nucleotide sequence of the target gene is applicable to plasmid, adenovirus (Lockett LJ. et al., Clinical Cancer Research 3:2075-2080 (1997)), adeno-associated virus (AAV) (Lashford LS. et al., Gene Therapy Technology, Application and Specifications A. Meager, 1999), retrovirus (Gunzburg WH et al., Retroviral vector. Gene Therapy Technology, Application and Specifications A. Meager, 1999), lentivirus (Wang G. et al., Journal of Clinical Research 104 (11): R55-62 (1999)), herpes simplex virus (Chamber R. et al., Proceedings of the National Academy of Sciences of the United States of America 92:1411-1415 (1995)), vaccinia virus (Puhlmann et al., Gene Therapy Technology, Application and Specifications A. Meager, 1999), M. et al., Human Gene Therapy, 10:649-657 (1999)), liposomes (Methods in Molecular Biology, 199, SC Basu and M. Basu (eds.), Human Press 2002) or non-ionic surfactant vesicles.

[0021] According to a specific embodiment, the gene delivery system used in the present invention is a viral vector.

[0022] More specifically, the virus is selected from the group consisting of a lentivirus, an adenovirus, an adeno-associated virus (AAV), a retrovirus, herpes simplex virus and vaccinia virus, most specifically a lentivirus.

[0023] In the present invention, when the gene delivery system is constructed based on a viral vector, the contacting step is performed according to a viral infection method known in the art. The above-cited documents describe infection of host cells with a viral vector.

[0024] As used herein, the term "immune cell" refers to any cell involved in the initiation or promotion of an immune response, more specifically immune effector cells. Immune cells include, but are not limited to, for example, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, and mast cells. More specifically, the immune cell is a natural killer cell.

[0025] As used herein, the term "freezing" or "cryopreservation" refers to maintaining cells stably for a long time in a low temperature state, more specifically, the low temperature state refers to an ultra-low temperature state of -70°C to -200°C. Generally, cells mutate at a rate of one in ten thousand during culture, and when cells undergo long-term subculture, the cell population may change and become different from the original cell population. In severe cases, cells may lose their own specific functions after subculture. In addition, cells may be infected by mycoplasma and the like during subculture. Due to these problems, cell cryopreservation allows cells to be frozen and stored before they lose their inherent properties and used when needed. The inventors first discovered that in immune cells, especially natural killer cells, which have a very low efficiency of gene transduction using lentiviral vectors, if such a freezing treatment is performed before gene transfer, the efficiency of gene transfer will be significantly improved. Compared with cryopreservation for long-term cell preservation, the freezing step performed in the present invention can be performed only for a short period of time.

[0026] The freezing of cells can be treated with cryoprotectants, which can minimize the damage to cells caused by inevitable ice crystal formation and ion and osmotic imbalance during freezing and thawing. The freezing medium can include, for example, dextran, albumin and / or dimethyl sulfoxide (DMSO) to improve the safety and stability of cells during the freezing process.

[0027] As used herein, the term "thawing" refers to the process of raising the temperature of frozen or cryopreserved cells until they become soft, living cells, thereby allowing them to resume life activities. Thawing can usually be quickly accomplished by taking the cryopreserved cells out of a liquid nitrogen tank and placing them in a 37°C constant temperature water bath.

[0028] Since the freezing and thawing process of the present invention is intended to improve the efficiency of gene transduction into cells rather than long-term storage of cells, the freezing (step (a) of the present invention) and thawing (step (b) of the present invention) of the present invention can be carried out without a time interval, and the thawing process can be started immediately after the freezing is completed, or an appropriate time interval can be left between the freezing and thawing processes as needed.

[0029] According to a specific embodiment, the method of the present invention further comprises, before step (a), culturing the immune cells isolated from the subject in vitro for 6 to 11 days. More specifically, the method further comprises culturing them for 6 to 9 days, more specifically 6 to 8 days, and most specifically about 7 days before step (a).

[0030] According to a specific embodiment, the method of the present invention further comprises, after step (b), culturing the thawed immune cells for 2 to 4 days. Specifically, the method further comprises, after step (b), culturing them for 3 to 4 days, more specifically 2 to 3 days, most specifically 2 days.

[0031] According to a specific embodiment, step (c) is to add a transforming growth factor-β activated kinase 1 mitogen activated protein kinase kinase kinase kinase (TAK1 MAPKKK) inhibitor, a TANK binding kinase 1 (TBK1) inhibitor or a combination thereof to the culture medium of the thawed immune cells.

[0032] Specifically, the TAK1 MAPKKKK inhibitor can be a compound represented by the following formula 1 or a pharmaceutically acceptable salt thereof:

[0033] Formula 1

[0034]

[0035] Specifically, the TBK1 inhibitor may be a compound represented by the following formula 2 or a pharmaceutically acceptable salt thereof:

[0036] Formula 2

[0037]

[0038] As used herein, the term "pharmaceutically acceptable salt" includes salts derived from pharmaceutically acceptable inorganic acids, organic acids or bases. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, p-toluenesulfonic acid, tartaric acid, acetic acid, trifluoroacetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, etc. Salts derived from suitable bases may include alkali metals (such as sodium), alkaline earth metals (such as magnesium) and ammonium.

[0039] In another aspect of the present invention, a natural killer cell expressing a target gene by the above method of the present invention is provided. The method of introducing a target gene and an immune cell (eg, a natural killer cell) introduced with the target gene have been described in detail, and thus are omitted to avoid unnecessary redundancy.

[0040] In another aspect of the present invention, a pharmaceutical composition for preventing or treating tumors or infectious diseases is provided, wherein the pharmaceutical composition comprises the natural killer cells of the present invention as an active ingredient.

[0041] In another aspect of the present invention, there is provided a method for preventing or treating a tumor or an infectious disease, comprising administering the natural killer cells of the present invention to a subject in need thereof.

[0042] When the present invention is applied to immune cells, it can be used to treat tumors and infectious diseases. The natural killer cells produced by the method of the present invention can be applied to all types of tumors, including solid cancers and blood cancers. Unlike blood cancers, solid cancers refer to cancers that form masses in organs, including cancers that occur in most organs. Tumors that can be treated using the natural killer cells of the present invention are not particularly limited, including but not limited to gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumors, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma, etc. Infectious diseases that can be treated using the immune cells of the present invention are diseases caused by infection with viruses or pathogens, including all diseases that may be caused by infection through respiratory organs, blood, skin contact, etc. These infectious diseases include, but are not limited to, for example, hepatitis B and C, human papillomavirus (HPV) infection, cytomegalovirus infection, viral respiratory diseases and influenza.

[0043] As used herein, the term "treatment" refers to (a) inhibiting the development of a disease, disorder or symptom; (b) alleviating a disease, disorder or symptom; or (c) eliminating a disease, disorder or symptom. When stem cells introduced with the immunogenicity suppressive composition of the present invention are administered to a subject, the stem cells are used to inhibit the development of symptoms caused by an excessive or undesirable immune response, or to eliminate or alleviate these symptoms. When immune cells introduced with the immunogenicity suppressive composition of the present invention are administered to a subject, the immune cells are used to induce the death of cancer cells or infected cells, thereby inhibiting the development of symptoms caused by a tumor or infectious disease, or to eliminate or alleviate these symptoms. Therefore, the composition of the present invention itself can be a cell therapeutic composition for a disease, or can be administered together with other pharmacological components and used as a therapeutic adjuvant for a disease. Therefore, as used herein, the term "treatment" or "therapeutic agent" includes the meaning of "therapeutic adjuvant" or "therapeutic auxiliary".

[0044] As used herein, the term "administering" or "administering" refers to directly administering a therapeutically effective amount of the composition of the present invention to a subject so that the same amount of the composition is formed in the body of the subject.

[0045] As used herein, the term "therapeutically effective amount" refers to a dose of a composition sufficient to provide a therapeutic or preventive effect to a subject to which the composition of the present invention is administered, and thus, the term is intended to include a "prophylactically effective amount."

[0046] As used herein, the term "subject" includes, but is not limited to, humans, rats, mice, guinea pigs, dogs, cats, horses, cows, pigs, monkeys, chimpanzees, baboons, or rhesus monkeys. Specifically, the subject of the present invention is a human.

[0047] In another aspect of the present invention, a method for improving the expression efficiency of a target gene in an immune cell is provided, comprising freezing the immune cell and thawing the frozen immune cell.

[0048] The immune cells used in the present invention, their freezing and thawing processes, and methods for delivering target genes have been described in detail and are therefore omitted to avoid unnecessary redundancy.

[0049] Beneficial effects

[0050] The features and advantages of the present invention are summarized as follows:

[0051] (a) The present invention provides a method for effectively expressing a target gene in immune cells, more specifically, in natural killer cells, using a viral vector.

[0052] (b) By adding a simple freezing and thawing process of natural killer cells before transduction, the method of the present invention significantly improves the transduction efficiency of viral vectors without adding enzymes or small molecules.

[0053] (c) The present invention is particularly useful for improving the efficiency of lentiviral vectors that have low gene transfer efficiency in natural killer cells, thereby obtaining natural killer cells introduced with desired genes to maximize the function, activity and productivity of the cells as a source of immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 The figure shows the expression efficiency of HER2 CAR introduced by lentiviral vector after freezing NK cells at different time points in culture and incubating them for 3 days from the time of freezing.

[0056] Figure 2 The figure shows the expression efficiency of HER2 CAR introduced by lentiviral vector in NK cells frozen or cultured without freezing at different time points after 3 days of culture.

[0057] Figure 3 The lentiviral vector transduction efficiency was compared according to the post-thawing culture period of frozen NK cells.

[0058] FIG4 compares the transduction efficiency of lentiviral vectors according to the culture period after thawing ( Figure 4a ), and compared the efficiency of frozen or unfrozen NK cells on day 10 of culture ( Figure 4b ), and the transduction efficiency was confirmed by FACS analysis.

[0059] Figure 5 shows the effect of using the enhancer BX795 ( Figure 5a ) and 5z-7-oxozeaenol (5z-7-oxozeaenol, Figure 5b ) The efficiency of delivering lentiviral vectors into NK cells.

[0060] Figure 6 shows the expression rate of CAR ( Figure 6a ) and vector copy number (VCN) values ​​( Figure 6b ) determined the transduction efficiency of lentiviral vectors expressing various CAR single-chain antibody fragments (scFv).

[0061] Invention method

[0062] Hereinafter, the present invention will be described in more detail with reference to examples. These examples are only used to explain the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention obtained according to the main content of the present invention is not limited by these examples. Example

[0063] Example 1: Comparison of lentiviral vector transduction efficiency of NK cells at different freezing times

[0064] 1-1) NK cell culture and freezing

[0065] Umbilical cord blood natural killer (CBNK) cells were isolated and cultured from human donors. On the first day of culture, the CBNK cells were stimulated and cultured with feeder cells, which were CD4+ T cells transduced with 4-1BB, membrane-bound interleukin-21 (mbIL-21), and membrane-type tumor necrosis factor-α (mTNF-α) genes. A medium containing 1% (vol / vol) human plasma, 1333 IU human interleukin-2 (Proleukin, Novartis, South Korea), and 4 mM glutamine (Hyclone) was added. Serum-free medium (Cellgenix) was used as NK cell culture medium, and the cell concentration was adjusted to 1 × 10 6 / mL for NK cell culture in a culture container of appropriate volume.

[0066] PBS (Irvine Scientific) containing 25% dextran-40 (Hospira), 20% albumin (Akron Biotech), and 5% dimethyl sulfoxide (Avantor) was used as cryopreservation medium. NK cells were frozen using a freezing container or an automated cell freezer and then stored in an ultra-low temperature freezer at -70°C or in an ultra-low temperature liquid nitrogen tank below -130°C until use.

[0067] 1-2) Lentiviral vector transduction of NK cells

[0068] The conditions for cell freezing, transduction, and expression detection at each time point of NK cell culture are shown in Table 1 below. Starting from day 0 (immediately after isolation), NK cells were cultured for 3, 5, 7, 9, 11, and 13 days, frozen and cryopreserved, and then thawed simultaneously. NK cells were co-cultured with NK medium for 3 days as a recovery period to prevent possible cell damage during freezing and thawing, and NK cells were transduced with anti-HER2 scFv CAR (HER2 CAR) genes. After thawing and culturing for 3 days, NK cells were counted using a hemocytometer and 3x10 were seeded in each well of a 48-well plate. 5NK cells. The lentiviral vector expressing the HER2 CAR gene was produced by the International Center for Genetic Engineering and Biotechnology (ICGM) (Daejeon, South Korea). In order to transduce HER2CAR into NK cells, a complex with a multiplicity of infection (MOI) of 20 was prepared, which was a complex of HER2 CAR lentiviral vector and 10 μg / mL of transduction enhancing peptide (Protransduzin, JPT, TE-PTDB-2). The complex was placed at room temperature for at least 5 minutes before being used for the treatment of NK cells in 48-well plates. 20 ng / mL of IL-21 (Biolegend / 571204) was supplemented in the culture medium to promote the intracellular introduction and expression of the lentiviral vector. On the second day after transduction, fresh NK cell culture medium containing 20 ng / mL of IL-21 was added equally to each well of the plate.

[0069] [Table 1] Time points for freezing, transduction and expression detection in NK cell culture

[0070] NK cells freezing Transduction Confirmation of CAR expression (transduction + 6 days) D0F-TD3 Day 0 Day 3 Day 9 D3F-TD6 Day 3 Day 6 Day 12 D5F-TD8 Day 5 Day 8 Day 14 D7F-TD10 Day 7 Day 10 Day 16 D9F-TD12 Day 9 Day 12 Day 18 D11F-TD14 Day 11 Day 14 Day 20 D13F-TD16 Day 13 Day 16 Day 22

[0071] 1-3) Confirmation of transfected gene expression in NK cells

[0072] The expression of HER2 CAR in NK cells cultured for 6 days after HER2 CAR transduction was determined by flow cytometry (FACS). NK cells cultured for 9 days after thawing without HER2 CAR transduction were used as HER2 CAR negative control. 5 NK cells were centrifuged at 1200 rpm for 5 minutes and the supernatant was removed, and then resuspended in 2 mL of FACS buffer with 2% FBS added. After centrifugation at 2000 rpm for 3 minutes to remove the supernatant, the precipitate was resuspended in 100 μL FACS buffer and reacted at 4 ° C for 30 minutes. The 100 μL FACS buffer contained 1 μL of recombinant human HER2 protein (R&D systems) with C-terminus coupled with 6× histidine and a concentration of 50 ng / μL. The test tubes used for subtype staining reacted with 100 μL of FACS buffer without recombinant human HER2 protein under the same conditions. The test tubes were then centrifuged at 2000 rpm for 3 minutes with 2 mL FACS buffer, and the supernatant was removed. For secondary staining, 100 μL FACS buffer was added to the washed NK cells, followed by the antibodies to be detected as shown in Table 2 and reacted at 4 ° C for 30 minutes. The cells were then washed with 2 mL of FACS buffer, fixed with 200 μL of fixative (BD, product number 554655), and analyzed for expression on the surface of NK cells by flow cytometry FACS (LSRFortessa model, BD Biosciences).

[0073] [Table 2] Antibodies used for FACS analysis to confirm the expression of anti-HER2 scFv CAR on NK cells

[0074] Markers Antibody (Fluorescence / Manufacturer / Cat. No.) Subtype HER2 CAR Anti-human CD56 PEcy7 / BD Biosciences / 557747 1μL 1μL Anti-human CD3 APC / BD Biosciences / 555335 4μL 4μL 7-AAD PerCp-Cy5.5 / Beckman Coulter / A07704 4μL 4μL Anti-6x Histidine PE / Abcam / Ab72467 1μL 1μL

[0075] By calculating the percentage of HER2 CAR positive expressing cells relative to subtype stained cells, the anti-HER2 scFv CAR gene transduction efficiency was compared in NK cells of 7-AAD-negative, CD3-negative, and CD56-positive phenotypes. When NK cells frozen on days 0, 3, and 5 were thawed and cultured for 3 days, and then transduced with lentiviral vectors on days 3 (D0F-TD3), 6 (D3F-TD6), and 8 (D5F-TD8), HER2 CAR expression was low, ranging between 8-9%. However, in NK cells transduced on day 10 (D7F-TD10) after thawing and culturing NK cells frozen on day 7 for 3 days, HER2CAR expression increased rapidly to 29.3%. In the same way, the expression of NK cells that were frozen on the 9th, 11th, and 13th days of culture, thawed, and cultured for 3 days decreased over time, reaching 26.4%, 20.5%, and 13.7% on the 11th day (D9F-TD11), 13th day (D11F-TD13), and 15th day (D13F-TD15), respectively. Figure 1 ). Figure 1 The detailed values ​​of the graphs are summarized in Table 3. Figure 1 As shown, when the cells were frozen, thawed and transduced with lentiviral vectors at different time points during NK cell culture, the gene expression efficiency of the cells frozen and transduced after the 7th day of culture was higher than that at the beginning of the culture, that is, the expression level was highest under D7F-TD10 conditions (freezing and thawing on the 7th day, and transducing on the 10th day after another 3 days of culture).

[0076] [Table 3] HER2 CAR expression percentage at different freezing and transduction time points

[0077] Freezing-transduction time HER2 CAR % (standard deviation) D0F-TD3 9.1(±3.6) D3F-TD6 8.5(±2.6) D5F-TD8 9.1(±5.0) D7F-TD10 29.3(±4.1) D9F-TD12 26.4(±2.0) D11F-TD14 20.5(±2.0) D13F-TD16 13.7(±4.8)

[0078] Example 2: Comparison of gene transduction efficiency of frozen and non-frozen NK cells

[0079] The detailed culture protocol and experimental conditions used to compare gene transduction efficiency of frozen and non-frozen NK cells are shown in Table 4. The HER2 CAR expression results were compared between frozen NK cells that were thawed and cultured for 3 days after gene transduction (frozen-thaw) and NK cells that were gene transduced after the same culture period but not frozen (fresh).

[0080] [Table 4] Time points for freezing, transduction and expression detection in NK cell culture

[0081]

[0082]

[0083] The experimental group that underwent the freezing and thawing process was subjected to cell culture and lentiviral vector transduction in the same manner as in Example 1. The NK cells in the non-frozen group were cultured without the freezing process after stimulation with feeder cells on day 0 of culture, and were transduced with lentiviral vectors on days 6, 8, 10, 12, 14 and 16 of culture, respectively. Gene transduction was performed in the same manner as in Example 1-2. All experimental groups were cultured for 6 days after gene transduction, and the expression of the transgene was then analyzed by flow cytometry (FACS) in the same manner as in Example 1-3. As a result, the expression efficiency of HER2 CAR (human epidermal growth factor receptor 2 chimeric antigen receptor) was found to be the highest in D7F-TD10 (i.e., frozen NK cells were thawed on day 7 of culture and then transfected on day 10 of culture). Figure 2 ). Figure 2 The detailed values ​​of the graphs in the table are summarized in Table 5. In addition, when the comparison was made on the 10th and 14th days of culture, the expression efficiency of HER2 CAR in NK cells transfected after freezing was higher than that in NK cells transfected without freezing. From the above results, it can be concluded that when transduced with lentiviral vectors after the same culture period, NK cells that have undergone a freeze-thaw process have a higher gene transduction efficiency, and freezing on day 7 of culture / transduction on day 10 (D7F-TD10) is the optimal condition for introducing exogenous genes into NK cells ( Figure 2 , Table 5).

[0084] [Table 5]

[0085]

[0086]

[0087] Example 3: Comparison of lentiviral vector transduction efficiency of NK cells at different culture days after thawing

[0088] Since the results of Examples 1 and 2 confirmed that NK cells frozen on day 7 of culture had the highest transduction efficiency, the transduction efficiency of lentiviral vectors was compared under the experimental conditions of Table 6 below according to the incubation period for cell recovery after thawing of NK cells frozen on day 7 of culture.

[0089] [Table 6] Time points for freezing, transduction and expression detection in NK cell culture

[0090]

[0091] The same experimental method as in Example 1-2 was adopted, and the lentiviral transduction was performed immediately after thawing (D7F-TD7), the first day of incubation after thawing (D7F-TD8), the second day of incubation after thawing (D7F-TD9), the third day of incubation after thawing (D7F-TD10), and the fourth day of incubation after thawing (D7F-TD11). Four lentiviral vectors (Lentigen, Maryland, USA) were used in this example, and the vectors expressed anti-HER2 scFv CAR (HER2 CAR), anti-CD5 scFv CAR (CD5 CAR), anti-CD19 scFv CAR (CD19 CAR) and GFP gene respectively. The expression of HER2 CAR, CD5 CAR and CD19 CAR in NK cells cultured for 6 days after transduction was determined in the same manner as in Example 1-3. The recombinant proteins used to analyze the expression of each gene and the antibodies used for secondary staining are summarized in Tables 7 and 8, respectively. After secondary staining, NK cells were fixed with 200 μL of fixative solution, and the transduction efficiency of CAR gene was compared by calculating the percentage of HER2CAR or CD5 CAR or CD19 CAR expression positive cells in 7-AAD-negative, CD3-negative, and CD56-positive cells relative to the subtype stained cells. The transduction efficiency of GFP gene was compared by calculating the mean FITC fluorescence intensity (MFI) value of 7-AAD-negative, CD3-negative, and CD56-positive cells relative to the negative control NKs.

[0092] [Table 7] Time points for freezing, transduction and expression detection in NK cell culture

[0093]

[0094] [Table 8] Antibodies used for FACS analysis to confirm transgene expression in NK cells

[0095]

[0096] The transgene expression levels of NK cells frozen on the 7th day of culture gradually increased on the 1st, 2nd, and 3rd days after thawing compared to when they were just thawed. Therefore, the transduction efficiency was the highest on the 3rd day after thawing, which was the tenth day of NK cell culture, and then the transduction efficiency decreased from the 4th day. The four different transfected genes all showed similar gene expression trends, confirming that the D7F-TD10 condition, that is, thawing the frozen cells on the 7th day of culture and then transfecting 3 days later, is the most efficient lentiviral vector transduction condition in NK cells ( Figure 3 ). Figure 3 The detailed values ​​of each graph are shown in Table 9.

[0097] [Table 9] Transgenic expression at different incubation times after thawing

[0098]

[0099] Example 4: Transduction of HER2 CAR into NK cells using the D7F-TD10 method

[0100] NK cells were cultured directly for ten days without freezing, and the transduction efficiency and HER2CAR expression at different time points were compared. For the 10-day culture condition, the transduction efficiency was compared with the D7F-TD10 condition, that is, the transduction efficiency of NK cells frozen on the 7th day of culture and thawed and cultured for 3 days. The detailed comparison conditions are shown in Table 10.

[0101] [Table 10] Time points for freezing, transduction and expression detection in NK cell culture

[0102] NK cells freezing Transduction Confirmation of CAR expression (+6 days after transduction) Not transduced not applicable not applicable Day 16 of incubation TD3 not applicable Day 3 Day 9 TD7 not applicable Day 7 Day 13 TD10 not applicable Day 10 Day 16 D7F-TD10 Day 7 Day 10 (thaw + 3 days) Day 16

[0103] Using the same method as in Example 1-1, NK cells derived from umbilical cord blood were cultured using feeder cells, and the HER2 CAR gene was transduced with a lentiviral vector on the 3rd, 7th and 10th day of culture, respectively. NK cells under D7F-TD10 conditions were frozen on the 7th day of culture, thawed and cultured for 3 days for HER2 CAR gene transduction. The specific gene transduction method is the same as in Example 1-2, that is, NK cells are treated with 20MOI of lentiviral vectors expressing HER2 CAR, 10 μg / mL pretransducin and 20ng / mL human IL-21 recombinant protein. In addition, NK cells were treated with (5Z)-7-oxozearalenol (TOCRIS, 3604) at a concentration of 6 μM, and the TOCRIS is a known inhibitor of transforming growth factor-β-activated kinase 1 (TAK1) that can be used as an enhancer to improve the efficiency of lentiviral transduction. One day after transduction, fresh NK cell culture medium containing 20 ng / mL of IL-21 and 6 μM (5Z)-7-oxozearalenol was added to each well of the culture plate in equal amounts. The HER2 CAR expression of NK cells cultured for 6 days after transduction was detected by FACS analysis in the same manner as in Example 1-3, expressed as a percentage. In the case where NK cells were not frozen, HER2 CAR expression increased with increasing culture time, with the highest HER2 CAR expression at TD10, but even if NK cells were cultured for the same time, the gene transduction efficiency under D7F-TD10 conditions was significantly higher ( Figure 4a). In addition, FACS scatter plot analysis comparing the expression of NK cells transfected with HER2 CAR under TD10 or D7F-TD10 conditions showed that the expression of HER2 CAR under D7F-TD10 conditions was more than 2 times higher than that under TD10 conditions, and the mean fluorescence intensity (MFI) was also more than 10 times higher ( Figure 4b )

[0104] Example 5: Comparison of gene transduction efficiency using different enhancers

[0105] The gene transduction efficiency under D7F-TD10 conditions was evaluated using enhancers that can improve the lentiviral transduction efficiency. The detailed experimental conditions are shown in Table 11.

[0106] [Table 11] Time points for freezing, transduction and expression detection in NK cell culture

[0107]

[0108] 5-1) Lentiviral vector transduction using enhancers and FACS expression analysis Using the same method as in Example 1-1, NK cells derived from umbilical cord blood were cultured using feeder cells, and the NK cells were transduced with a lentiviral vector expressing HER2 CAR and IL-15 genes at the same time under the conditions of D7F-TD10 on the 3rd day of culture, the 10th day and the D7F-TD10 respectively. The specific gene transduction method is the same as in Example 1-2, that is, NK cells are treated with 20MOI of lentiviral vectors expressing HER2 CAR and IL-15, 10 μg / mL pretransducin and 20ng / mL human IL-21 recombinant protein. In addition, in order to improve the efficiency of lentiviral transduction, NK cells were treated with (5Z)-7-oxozearalenol (TOCRIS, 3604) at a concentration of 6 μM or TBK1 inhibitor BX795 (TOCRIS, 4318) at a concentration of 1.5 μM as an enhancer. One day after transduction, fresh NK cell culture medium containing 20 ng / mL of IL-21 and 6 μM (5Z)-7-oxozearalenol or 1.5 μM BX795 was added to each well of the culture plate and incubated. The HER2 CAR expression of NK cells cultured for 6 days after transduction was analyzed by FACS analysis in the same manner as in Example 1-3, and expressed as a percentage value.

[0109] Regardless of the type of enhancer used, both enhancers resulted in the highest HER2CAR expression in NK cells frozen on day 7 of culture and transfected on day 10 (D7F-TD10 condition) compared to TD3 and TD10 conditions ( Figure 5a ).

[0110] 5-2) Cell culture to confirm IL-15 secretion in transduced cells

[0111] NK cells were cultured for 6 days after transduction, and HER2 CAR-positive cells were isolated as follows to confirm the expression of IL-15. NK cells were centrifuged at 1200 rpm for 5 minutes, the supernatant was removed and the pellet was resuspended in MACS buffer (PBS containing 0.5% FBS, 2 mM EDTA) to a cell concentration of 1x10 7 Add 1x10 6 1.5 μL of 50 ng / mL biotin-labeled recombinant human-HER2 protein (Acrobiosystems, HE2-H822R) was added to each NK cell and incubated at 4°C for 30 minutes. MACS buffer (10 times the volume of NK cells) was added and centrifuged at 340g, 4°C for 10 minutes to remove the supernatant. The cells were resuspended in MACS buffer to a concentration of 1×10 8 After adding 4x 10 7 37.5 μL of anti-biotin microbeads (Miltenyi Biotec, 130-092-357) were added to NK cells / mL and incubated at 4°C for 30 minutes. MACS buffer 10 times the volume of NK cells reacted with microbeads was added, and then centrifuged at 340g and 4°C for 10 minutes to remove the supernatant.

[0112] The LS column (Miltenyi Biotec) was installed on a QuadroMACSTM separator (Miltenyi Biotec) and rinsed with 3 mL of MACS buffer to activate the column. The NK cells reacted with the magnetic beads were fully released by pipetting, and 500 μL was loaded into each column, and then washed three times with 3 mL of MACS buffer. After rinsing, the column was removed from the QuadroMACSTM separator, 5 mL of MACS buffer was added, and the CAR-positive cells in the column were separated using a push rod. The separated cells were centrifuged at 1×10 6 The cells were resuspended in NK cell culture medium at a concentration of 100 / mL, placed in a well plate of appropriate specifications, and restimulated with feeder cells in the same manner as in Example 1-1 and cultured for another 13 days. The NK cells cultured for a total of 29 days were frozen and stored in an ultra-low temperature liquid nitrogen tank for use.

[0113] 5-3) Confirmation of IL-15 secretion

[0114] To determine the expression of IL-15 introduced simultaneously with HER2 CAR, frozen NK cells were thawed on the 29th day of culture, and the secretion of IL-15 after co-culture with the target cancer cell line was determined by ELISA. HCC1954 (American Type Culture Collection, Manassas, Virginia, USA), a HER2-positive human breast cancer cell, was used as the target cancer cell line. The target cells were centrifuged at 1200 rpm for 5 minutes with the detection medium (RPMI 1640 medium containing 10% FBS, Gibco, 11875093), the supernatant was discarded, and the cell pellet obtained after washing was resuspended in the detection medium to a cell concentration of 6x10 5 / mL. After thawing, the frozen NK cells were prepared in the assay medium at a concentration of 2x10 6 / mL solution. Prepare a 96-well round-bottom culture plate and add 100 μL of prepared target cells and NK cells to each well for co-culture. For the control group of NK cells alone, add 100 μL of detection medium to 100 μL NK cells instead of target cells. After 24 hours of co-culture, remove the culture plate, centrifuge at 2000 rpm, 4°C for 3 minutes, collect 170 μL of supernatant, and measure IL-15 expression using an IL-15 ELISA kit (R&D systems, S1500). In summary, the highest value of the standard concentration was prepared as 250 pg / mL, and then diluted by 1 / 2, resulting in a total of seven standards (250, 125, 62.5, 31.25, 15.63, 7.81, 3.91 pg / mL), including the lowest value of 3.9 pg / mL. In a 96-well plate pre-coated with the antibody provided by the ELISA kit, add 50 μL of sample and standard to each well, and add 50 μL of dilution buffer to the standard blank well. After standing at room temperature for 3 hours, wash each well four times with 300 μL of wash buffer. Add 200 μL of human IL-15 conjugate to each well and leave it at room temperature for 45 minutes. Wash each well four times with 300 μL of wash buffer. Add 200 μL of substrate solution made by mixing equal volumes of solution A and solution B to each well, leave it at room temperature for 30 minutes, then add 50 μL of stop solution to each well and gently mix the solution. Use a Spectra max190 instrument to measure the absorbance at a wavelength of 450 nm to calculate the IL-15 expression in the sample.

[0115] When co-cultured with HER2 CAR-positive target cells HCC1954, IL-15 expression was highest under D7F-TD10 conditions, i.e., when frozen and thawed on day 7 and gene introduced on day 10. On the other hand, in the control condition with only NK cells and no target cells, low IL-15 expression of less than 5 pg / mL was shown, and there was no significant difference depending on the time of gene introduction ( Figure 5b ). As shown in the above results, even when various enhancers for improving the transduction efficiency of lentiviral vectors were used, the D7F-TD10 method showed the highest gene transduction efficiency ( FIG. 5 ).

[0116] Example 6: Comparison of lentiviral vector transduction efficiency and vector copy number (VCN)

[0117] The gene transduction efficiency of D7F-TD10 conditions was evaluated according to the type of delivery system used for lentiviral transduction. The detailed experimental conditions are shown in Table 12.

[0118] [Table 12] Time points for freezing, transduction and expression detection in NK cell culture

[0119]

[0120] NK cells were transfected with lentiviral vectors expressing HER2 CAR, CD5 CAR, and CD19 CAR under TD3 and D7F-TD10 conditions in the same manner as in Example 3. For D7F-TD10 (L) conditions, NK cells were suspended in NK cell culture medium to a concentration of 1 x 10 6 / mL, and in the presence of Lentiboost-P (sirion biotec, P grade) accounting for 1 / 100 of the total volume and human IL-21 recombinant protein (Biolegned) at a concentration of 20ng / mL, 20MOI of lentiviral vector transfection.NK cells without lentiviral vectors are used as negative controls.Three lentiviral vectors expressing anti-HER2 scFv CAR (HER2 CAR), anti-CD5scFv CAR (CD5 CAR) and anti-CD19 scFv CAR (CD19 CAR) genes are used, and the lentiviral vectors are all produced from Lentigen (Maryland, USA). The expression of HER2 CAR, CD5 CAR and CD19 CAR in NK cells cultured for 6 days after transduction is determined by the same method as in Example 1-3. After secondary staining, NK cells are fixed with 200 μL of fixative, and the percentage value of CAR protein expression on the surface of NK cells is analyzed by FACS equipment with the lowest expressed TD3 value of 1. The expression values ​​of D7F-TD10 or D7F-TD10(L) using Protransduzen or Lentiboost-P as delivery agents were calculated as the ratio to TD3 cells, where the expression of TD3 cells was scaled to 1. Comparison of gene expression showed that all various scFv CARs showed high gene expression efficiency under D7F-TD10 conditions regardless of the type of delivery agent ( Figure 6a In addition, to measure VCN to determine the extent of integration of lentiviral vectors in NK cells, genomic DNA was extracted from the same NK cells used for the above experiments and real-time PCR was performed. Tissue (MachereyNagel, 740952.250) kit was used for genomic DNA extraction, and the concentration of the final extracted genomic DNA was measured by a micro-spectrophotometer (nano-drop), and then the DNA concentration was diluted to 10-50 ng / uL using nuclease-free ultrapure water (Ambion, AM9937). The standard DNA, primers and probe information for real-time PCR are summarized in the following Tables 13 and 14.

[0121] [Table 13] Information of standard DNA used for VCN measurement

[0122]

[0123] [Table 14] Real-time PCR primers and probes

[0124]

[0125]

[0126] To determine the VCN of anti-HER2 scFv CAR, anti-HER2 scFv CAR and RPPH1 (4x10 7 10 copies / uL) of standard DNA stock solutions were mixed in equal amounts and then diluted stepwise with nuclease-free ultrapure water to prepare 2×10 (STD1), 2×10 2 (STD2), 2×10 3 (STD3), 2×10 4 (STD4) and 2×10 5 (STD5) copies / uL standard. The spike control was prepared by mixing a 1 / 5 dilution of STD3 with an equal amount of wild-type NK cell genomic DNA (25ng / μL). The PCR control for the anti-HER2 scFv CAR target was prepared with 10ng / μL genomic DNA from wild-type NK cells, and the PCR blank control used nuclease-free ultrapure water. The genomic DNA of the NK cells of the VCN to be tested was diluted to 10ng / μL with a nuclease-free premix. For each well of the target gene, prepare the PCR premix according to the volume shown in Table 15.

[0127] [Table 15] PCR reagents for VCN measurement of anti-HER2 scFv CARs

[0128]

[0129] Be prepared Optical 96-well reaction plate (Applied Biosystems, N8010560), 5 μL PCR template and 20 μL premix were added to each well, and then the PCR reaction was performed according to the cycle in Table 17. Based on the standard curve, the copy number of CAR and RPPH1 genes of each sample was calculated, the number of cells was estimated by the calculated RPPH1 copy number, and the copy number of CAR was divided by the estimated number of cells to calculate the VCN of the CAR gene of each NK cell. VCN was calibrated according to the CAR expression rate (%) of each NK cell to calculate the final VCN.

[0130] The VCN assay for anti-CD5 and anti-CD19 scFv CARs was performed in the same manner as for the anti-HER2 scFv assay described above: Prepare the standard plasmids in Table 13, the primers and probes in Table 14, and the PCR master mix in the volumes shown in Table 16. Optical 96-well reaction plate (Applied Biosystems, USA, N8010560), 5 μL PCR template and 20 μL premix were added to each well, and PCR reaction was performed according to the cycle in Table 17.

[0131] [Table 16] PCR reagents for VCN measurement of anti-CD5 and anti-CD19 scFv CARs

[0132]

[0133] [Table 17] PCR cycles for VCN measurement

[0134]

[0135] VCN is a gene transduction indicator used to calculate the number of lentiviral vectors inserted into a single cell. The VCN under the condition of transfection on day 3 of culture (i.e., TD3) was set to 1, and the relative VCN under each condition was calculated according to the ratio to TD3 VCN to compare the differences. Regardless of the transduction type, when the D7F-TD10 method was used for gene transduction, all various scFvCARs showed higher VCN values ​​than TD3 ( Figure 6b ). Based on the above results, it can be concluded that NK cells that were frozen on the 7th day of culture, thawed and cultured for 3 days, and transduced with lentiviral vectors on the 10th day of culture showed higher gene introduction and expression efficiency.

[0136] Although the present invention has been described in detail with reference to specific features, it is obvious to those skilled in the art that this description is only a preferred embodiment of the present invention and does not limit the scope of the present invention. Therefore, the true scope of the present invention will be defined by the appended claims and their equivalents.

Claims

1. A method for expressing a target gene in an immune cell, the method comprising: (a) Frozen immune cells; (b) thawing the frozen immune cells; and (c) Introducing a gene delivery system containing a target gene into thawed immune cells.

2. The method according to claim 1, characterized in that The method further comprises culturing the immune cells isolated from the subject in vitro for 6 to 11 days prior to step (a).

3. The method according to claim 1, characterized in that The method further comprises culturing the thawed immune cells for 2-4 days after step (b).

4. The method according to claim 1, characterized in that The immune cells are selected from the group consisting of T cells, natural killer (NK) cells and natural killer T (NKT) cells.

5. The method according to claim 1, characterized in that The gene delivery system is a viral vector.

6. The method according to claim 5, characterized in that The virus is selected from the group consisting of lentivirus, adenovirus, adeno-associated virus (AAV), retrovirus, herpes simplex virus and vaccinia virus.

7. The method according to claim 6, characterized in that The virus is a lentivirus.

8. The method according to claim 1, characterized in that The step (c) is carried out by adding one or more components selected from the group consisting of: a compound of Formula 1, a compound of Formula 2, and a pharmaceutically acceptable salt thereof Formula 1 Formula 2 9. A natural killer cell, wherein the natural killer cell expresses a target gene by the method according to any one of claims 1 to 8.

10. A pharmaceutical composition for preventing or treating tumors or infectious diseases, comprising the natural killer cells according to claim 9 as an active ingredient.

11. A method for improving the expression efficiency of a target gene in immune cells, the method comprising freezing the immune cells, and thawing the frozen immune cells.

12. The method according to claim 11, characterized in that The target gene is inserted into a viral vector and introduced into immune cells.

13. The method according to claim 12, characterized in that The virus is a lentivirus.

14. The method according to claim 11, characterized in that The immune cells are selected from the group consisting of T cells, natural killer (NK) cells and natural killer T (NKT) cells.